Information Provided By:
Fly News Breaks for May 22, 2019
May 22, 2019 | 08:11 EDT
Jefferies analyst Maury Raycroft lowered his price target for BioCryst Pharmaceuticals to $8 from $13 while keeping a Buy rating on the shares. The analyst still believes BCX7353 gets approved and used in the prophy setting, but he admits that use may be more limited with more reliance on pricing strategies following yesterday's Phase 3 data.
News For BCRX From the Last 2 Days
There are no results for your query BCRX